Table 2 Immune function parameters in peripheral blood leukocytes before (T0) and after 2 months (T2). Each value is the mean ± standard deviation of the data obtained from 31 men and women. “Placebo group” (N = 11) slept on normal beds; “Experimental group” (N = 20) used the HOGO system to avoid electromagnetic fields (EMFs). c.p.m. = counts per minute; N.S = statistically non-significant; T* = statistical tendency respect to T0
Placebo Group | Experimental Group | |||||
|---|---|---|---|---|---|---|
Parameters | T0 | T2 | p-value | T0 | T2 | p-value |
Neutrophil Adherence (Adherence Index) | 53 ± 17 | 51 ± 14 | 0.77 (N.S) | 37 ± 16 | 45 ± 26 | 0.18 (N.S) |
Lymphocyte Adherence (Adherence Index) | 50 ± 17 | 48 ± 11 | 0.71 (N.S) | 56 ± 19 | 35 ± 15 | 0.06 (*T) |
Phagocytic efficacy (% neutrophil ingesting) | 83 ± 16 | 83 ± 13 | 0.77 (N.S) | 93 ± 7 | 91 ± 5 | 0.6 (N.S) |
Basal lymphoproliferation (c.p.m.) | 1115 ± 250 | 1281 ± 560 | 0.6 (N.S) | 1176 ± 791 | 707 ± 291 | 0.09 (*T) |
IL-10concentrations (pg/mL) | 498.12 ± 229.7 | 111.31 ± 24.96 | 0.6 (N.S) | 320.275 ± 90.4 | 190.69 ± 90.39 | 0.1 (N.S) |
IL-4 concentrations (pg/mL) | 104.22 ± 4.34 | 108.3 ± 5.2 | 0.99 (N.S) | 39.67 ± 11.19 | 34.95 ± 19.78 | 0.98 (N.S) |
IL-6 concentrations (pg/mL) | 6574.9 ± 1301 | 5069.9 ± 1754.7 | 0.8 (N.S) | 7100.2 ± 950.2 | 7130.1 ± 870.1 | 0.9 (N.S) |
TNF-α concentrations (pg/mL) | 1820.6 ± 596.8 | 2283.3 ± 1501.9 | 0.78 (N.S) | 1069.9 ± 442.8 | 1088.5 ± 517.9 | 0.97 (N.S) |